145 related articles for article (PubMed ID: 34761338)
1. Silencing Akt1 enhances the resistance of prostate cancer cells to starvation and inhibits starvation-induced lung metastasis through epithelial-mesenchymal transition in prostate cancer.
Yang M; Liu H; Qiu GP; Gao F
Med Oncol; 2021 Nov; 39(1):8. PubMed ID: 34761338
[TBL] [Abstract][Full Text] [Related]
2. Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.
Alwhaibi A; Verma A; Artham S; Adil MS; Somanath PR
Biochem Pharmacol; 2019 Oct; 168():1-13. PubMed ID: 31202735
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.
Gao F; Alwhaibi A; Sabbineni H; Verma A; Eldahshan W; Somanath PR
Cancer Lett; 2017 Aug; 402():177-189. PubMed ID: 28602980
[TBL] [Abstract][Full Text] [Related]
4. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.
Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H
Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
Jin Y; Cui Z; Li X; Jin X; Peng J
Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
[TBL] [Abstract][Full Text] [Related]
7. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.
Wang L; Song G; Tan W; Qi M; Zhang L; Chan J; Yu J; Han J; Han B
Oncotarget; 2015 Nov; 6(34):35978-90. PubMed ID: 26451614
[TBL] [Abstract][Full Text] [Related]
8. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-κB pathway.
Zhang J; Kuang Y; Wang Y; Xu Q; Ren Q
Apoptosis; 2017 Jun; 22(6):877-884. PubMed ID: 28374086
[TBL] [Abstract][Full Text] [Related]
9. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
10. CDT1 facilitates metastasis in prostate cancer and correlates with cell cycle regulation.
Wang C; Che J; Jiang Y; Chen P; Bao G; Li C
Cancer Biomark; 2022; 34(3):459-469. PubMed ID: 35253732
[TBL] [Abstract][Full Text] [Related]
11. Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover.
Gao F; Alwhaibi A; Artham S; Verma A; Somanath PR
Br J Cancer; 2018 May; 118(11):1464-1475. PubMed ID: 29755115
[TBL] [Abstract][Full Text] [Related]
12. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin.
Chen L; Mai W; Chen M; Hu J; Zhuo Z; Lei X; Deng L; Liu J; Yao N; Huang M; Peng Y; Ye W; Zhang D
Pharmacol Res; 2017 Sep; 123():130-142. PubMed ID: 28712972
[TBL] [Abstract][Full Text] [Related]
13. Novel role of LLGL2 silencing in autophagy: reversing epithelial-mesenchymal transition in prostate cancer.
Hong GL; Kim KH; Kim YJ; Lee HJ; Cho SP; Han SY; Yang SW; Lee JS; Kang SK; Lim JS; Jung JY
Biol Res; 2024 May; 57(1):25. PubMed ID: 38720397
[TBL] [Abstract][Full Text] [Related]
14. Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT.
Zhao Y; Cai C; Zhang M; Shi L; Wang J; Zhang H; Ma P; Li S
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2013-2023. PubMed ID: 33772606
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
17. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.
Wang Z; Hulsurkar M; Zhuo L; Xu J; Yang H; Naderinezhad S; Wang L; Zhang G; Ai N; Li L; Chang JT; Zhang S; Fazli L; Creighton CJ; Bai F; Ittmann MM; Gleave ME; Li W
Neoplasia; 2021 Nov; 23(11):1147-1165. PubMed ID: 34706306
[TBL] [Abstract][Full Text] [Related]
18. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin.
Deep G; Jain AK; Ramteke A; Ting H; Vijendra KC; Gangar SC; Agarwal C; Agarwal R
Mol Cancer; 2014 Feb; 13():37. PubMed ID: 24565133
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract][Full Text] [Related]
20. The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Elshafae SM; Kohart NA; Altstadt LA; Dirksen WP; Rosol TJ
Prostate; 2017 May; 77(7):776-793. PubMed ID: 28181686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
